Abstract
The most recent guidelines on heart failure of the European Society of Cardiology were published in 2021. These guidelines devide patients according to the ejection fraction of the left ventricle into the group with reduced, mildly reduced and preserved ejection fraction.
The guidelines follow the recent evidence based medicine and clinical studies in their recommendations. A novel group of drugs aiming to reduce morbidity and mortality and to improve the quality of life in patients with reduced ejection frations are SGLT2 inhibitors - gliflozins.
The guidelines of the American Society of Cardiology set the treatment by gliflozins regardless of ejection fracion. The guidelines point out the treatment of comorbidities like diabetes, iron deficiency or tumors.
A complex approach of patients with heart failure including heart failure clinics is presented.